Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BTK |
| Variant | T474L |
| Impact List | missense |
| Protein Effect | gain of function - predicted |
| Gene Variant Descriptions | BTK T474L lies within the protein kinase domain of the Btk protein (UniProt.org). T474L results in increased kinase activity as demonstrated by increased autophosphorylation of Y223 in cell culture (PMID: 33526860), and therefore, is predicted to lead to a gain of Btk protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
BTK mutant BTK act mut BTK T474L |
| Transcript | NM_000061.3 |
| gDNA | chrX:g.101356197_101356198delACinsCT |
| cDNA | c.1420_1421delACinsCT |
| Protein | p.T474L |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_000061.2 | chrX:g.101356197_101356198delACinsCT | c.1420_1421delACinsCT | p.T474L | RefSeq | GRCh38/hg38 |
| NM_000061.3 | chrX:g.101356197_101356198delACinsCT | c.1420_1421delACinsCT | p.T474L | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK T474L | Advanced Solid Tumor | predicted - sensitive | Ibrutinib | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with Imbruvica (ibrutinib) resulted in reduced Btk activity in cell lines expressing BTK T474L in culture (PMID: 33526860). | 33526860 |